Heminevrin (Clomethiazole)

Heminevrin is indicated for conditions that require controlled sedation and management of withdrawal symptoms. It is typically prescribed in a clinical setting where careful monitoring is possible.

• Treatment of alcohol withdrawal syndrome to reduce the risk of seizures and delirium tremens
• Short‑term sedation for patients requiring rapid calming effects
• Adjunct therapy in intensive care units for sedation of mechanically ventilated patients
• Management of acute agitation when other agents are unsuitable
• Use in hospital protocols for detoxification programs under physician guidance

Clomethiazole may cause a range of side effects, some of which are more frequently observed than others.

Common

• Drowsiness or excessive sleepiness
• Dizziness or light‑headed feeling
• Nausea or mild gastrointestinal upset
• Headache
• Dry mouth
• Transient visual disturbances

Serious

• Respiratory depression, especially at higher doses
• Severe hypotension or cardiovascular instability
• Hepatic dysfunction or elevated liver enzymes
• Allergic reactions such as rash, itching, or swelling
• Confusion or delirium in susceptible individuals
• Dependence or withdrawal symptoms with abrupt discontinuation

Before initiating Heminevrin therapy, several safety considerations should be reviewed to minimize risk.

• Assess liver function, as clomethiazole is metabolized hepatically
• Use caution in patients with a history of respiratory disorders or sleep apnea
• Avoid use in individuals with known hypersensitivity to clomethiazole or related compounds
• Monitor blood pressure and heart rate during initial dosing
• Evaluate for potential abuse or dependence, especially in long‑term use
• Pregnancy and lactation status should be determined; the safety profile is not well established
• Ensure the patient is in a setting where respiratory function can be observed

Clomethiazole can interact with other medications, altering its efficacy or safety profile.

Avoid

• Other central nervous system depressants (e.g., benzodiazepines, opioids, barbiturates) due to additive sedation and respiratory risk
• Alcohol, which can potentiate CNS depression
• Strong CYP2C19 inhibitors that may increase clomethiazole plasma levels

Use with caution

• Antihypertensive agents, as clomethiazole may enhance blood pressure‑lowering effects
• Anticonvulsants, which could modify seizure threshold
• Drugs affecting hepatic enzymes (e.g., rifampin) that may reduce effectiveness
• Medications with sedative properties such as antihistamines or certain antidepressants